# What a CRO does, and what you can do yourself

No rule requires a CRO; a sponsor may hand any study duty to one in writing, but the responsibility for the data stays with the sponsor.

Canonical: https://signalment.app/guides/what-a-cro-does-and-what-you-can-do-yourself/
Updated: 2026-11-09

No part of a veterinary field study has to be done by a contract research organization. 21 CFR 511.1(f) lets a sponsor transfer any or all of its obligations to a CRO in writing, and VICH GL9 lets it delegate any or all of its study duties, but GL9 adds that the ultimate responsibility for the quality and integrity of the data always stays with the sponsor. What a CRO brings is people who have done the work before: a trained monitor who is not the investigator, protocol and report writers, a statistician, someone who files with FDA, and a quality auditor. A sponsor that has those people, or hires them one at a time, can run the study itself. The design decides how many it needs: an observational study needs few of them, and a study of an unapproved drug meant to support approval needs every one.

## What the rules say about a CRO

21 CFR 511.1(f)(1) defines a contract research organization as a person that assumes, as an independent contractor with the sponsor, one or more of the sponsor's obligations, "e.g., design of a protocol, selection or monitoring of investigations, evaluation of reports, and preparation of materials to be submitted to FDA." GL9's definition (1.10) adds that a CRO can be "an individual or organization," so a freelance monitor on contract is one. Under 511.1(f)(2) the transfer "shall be in writing," and "any obligation not covered by the written description shall be deemed not to have been transferred." Under 511.1(f)(3) a CRO that fails an obligation it took on faces the same regulatory action as a sponsor.

Guidance #85, FDA's text of VICH GL9, says the same in section 4.3: a sponsor "may delegate any or all of the sponsor's study-related duties and functions to a CRO" (4.3.1), in writing (4.3.2), and keeps what it does not delegate (4.3.3).

## The jobs, and who can do them

The sponsor's duties under GL9 section 4.2 and 511.1(b), and what keeping each one takes:

| Job | Where the rule puts it | What keeping it takes |
|---|---|---|
| Protocol | GL9 4.2.6, 4.2.7: drafted with the investigator, signed by both | A writer for the GL9 6.3 checklist, statistics included (6.3.17) |
| Notice to FDA | 511.1(b)(4); GL9 4.2.2 | Someone to file the notice before the product ships |
| Investigators | 511.1(b)(7)(i); GL9 4.2.3 | A qualified veterinarian at each site, with a current CV (GL9 3.2.1) |
| Monitoring | 511.1(b)(8)(ii); GL9 4.2.4 | A trained monitor who is not the investigator |
| Investigational product | GL9 4.2.12, 4.2.13 | Labelling, shipment records, and final disposal of what is left |
| Adverse events | 511.1(b)(8)(ii); GL9 4.2.10 | Someone who reads every report and reports on time |
| Data capture | GL9 8.3.1, 8.3.6 | Entries made under each person's electronic signature, changes kept in an audit trail |
| Quality audit | GL9 4.2.16, 8.1.2 | An auditor who certifies the audit in a report to the sponsor |
| Final study report | GL9 7.1.2, 7.2 | Authors who sign it: the sponsor, the investigator or both |

Monitoring is the one job the people running the site cannot do themselves (GL9 3.1.5). GL9 5.1 asks for a monitor trained in quality control and data verification, who visits "before, during and after the study" (5.2.6) and ends with "a signed and dated summary report of the contacts, visits made and activities witnessed" (5.2.14).

## How the design changes the answer

Observational, nothing assigned: no notice to FDA and no investigational product. GL9 leaves out studies "not intended to be used for regulatory support" (2.6). Draft Guidance #282 still recommends that "all studies conducted with client-owned companion animals use an ICF and be conducted in accordance with Good Clinical Practice (GCP) guidelines." The work is a protocol, a consent form, a site and a data system; no rule calls for outside help.

A marketed product used as its label directs: no notice to FDA. If the data are meant for a submission, GL9 is the standard, and with it the monitor and the audit. With an approved drug, adverse events go to the drug's applicant: a nonapplicant "must forward reports of adverse drug experiences to the applicant within 3 working days" (21 CFR 514.80(b)(3)), and the applicant reports each serious, unexpected event to FDA within 15 working days (514.80(b)(2)(i)).

An unapproved product, such as a peptide or a compounded drug: every row of the table applies. The notice goes in before shipment. The investigator keeps receipt and disposition records for two years after the study ends or the drug is approved (511.1(b)(7)(ii)). The sponsor provides current monitoring by a qualified person and promptly reports findings that suggest significant hazards to FDA and every investigator (511.1(b)(8)(ii)). A study meant to support approval follows "a standard of conduct acceptable to FDA," and its protocol says so (514.117(b)(2)). 21 CFR 11.1(b) brings the electronic records kept under these rules into Part 11, which applies to records kept "under any records requirements set forth in agency regulations." A sponsor without regulatory and monitoring staff hands over more here than in the other two designs. There is more in [When a pet study needs an INAD](/guides/when-a-pet-study-needs-an-inad/).

## What to ask a CRO before you sign

1. Which of our obligations will you assume? List each in the contract; under 511.1(f)(2) anything left out stays ours.
2. Will the INAD notice name you and list those obligations, as 511.1(b)(4)(vi) asks?
3. Who monitors, with what training, how often at each site, and will we get the summary report GL9 5.2.14 describes?
4. Whose data system holds the records, and can we take a complete copy with its audit trail at any time, including when the contract ends?
5. How do adverse events reach us, within how many days, and who drafts the report to FDA?
6. Who writes the final study report, who audits the study, and do both reports come to us?
7. Which jobs could we keep, and what is the price without them?

## What stays with you and the investigator

Whoever does the work, the sponsor owns the protocol, signed with the investigator; the decision whether the study needs a notice to FDA, and the filing and reporting that follow; the ethics review, where an institution or funder requires one; and the consent text owners read, which draft Guidance #282 says should state that the product is investigational and that its safety and effectiveness have not been demonstrated. Before or when its people first sign FDA-required records electronically, the organization sends FDA a letter certifying that those signatures are the legally binding equivalent of handwritten ones (FDA's 2024 electronic systems guidance, Q29). The investigator obtains each owner's consent before the animal takes part (GL9 3.2.13), keeps the study records, and promptly tells the sponsor of adverse events (3.2.17). A CRO can take on some of the sponsor's part under a written transfer, and the responsibility for the data stays with the sponsor even then (GL9 4.3.1). A data system takes on none of it.

## Where a data system fits

The same guidance, which CVM co-issued, treats hosted software as an IT service (section III.C). Before choosing one, the sponsor reviews the provider's validation, access controls, copies, backups and audit trails, then signs a written agreement that includes access to the data through the retention period; obligations not lawfully transferred to the provider stay with the sponsor (Q17).

Signalment is a data system, not a CRO. It holds the protocol and consent versions, case report forms, the owner diary and eConsent, randomization with a logged code break, monitor queries, electronic signatures, an audit trail a monitor can verify offline, a database lock with a fingerprint, and the exports. It offers a validation summary and the test suite behind it, and the Enterprise plan includes a signed quality agreement. It does not write protocols, monitor sites, file with FDA or audit a study, and a drug accountability ledger and SAS exports are not built yet. There is more on the [sponsor page](https://signalment.app/sponsors/).

## Sources

- 21 CFR 511.1, new animal drugs for investigational use: https://www.ecfr.gov/current/title-21/section-511.1
- 21 CFR 514.117, adequate and well-controlled studies: https://www.ecfr.gov/current/title-21/section-514.117
- 21 CFR 514.80, adverse event reporting for approved new animal drugs: https://www.ecfr.gov/current/title-21/section-514.80
- 21 CFR 11.1, scope of Part 11: https://www.ecfr.gov/current/title-21/section-11.1
- FDA Guidance #85, VICH GL9, Good Clinical Practice: https://www.fda.gov/media/70333/download
- FDA Guidance #282, Informed Consent Forms for Studies that Enroll Client-Owned Companion Animals, draft, September 2023: https://www.fda.gov/media/172056/download
- FDA, Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers, October 2024: https://www.fda.gov/media/166215/download
